Berotec 0.05% is a prescription-only inhalation solution containing the active component fenoterol hydrobromide. Its primary therapeutic domain is the management of reversible airway narrowing associated with certain respiratory conditions.

Quick Facts

• Assists in the management of acute episodes of asthma.
• Supports relief for reversible narrowing of the airways, such as in chronic obstructive bronchitis.
• May contribute to the temporary prevention of airway narrowing linked to physical exertion (exercise-induced asthma).

This medication is specifically indicated for the symptomatic treatment of acute asthma attacks and other conditions characterized by reversible obstruction of the airways, including chronic obstructive bronchitis. It may also be used as prophylaxis for exercise-induced asthma. The use of this drug is part of a patient's overall care plan and should be considered in conjunction with a foundation of anti-inflammatory treatment, especially for long-term respiratory conditions.

Who can and cannot use Berotec 0.05%

The eligibility for using Berotec 0.05% (Fenoterol hydrobromide) is strictly defined by regulatory documents based on patient characteristics and existing health conditions.

Contraindicated Populations

Berotec 0.05% is contraindicated (must not be used) in patients diagnosed with hypertrophic obstructive cardiomyopathy or tachyarrhythmia (abnormally fast heart rhythms). It is also prohibited for individuals with known hypersensitivity to the active ingredient, fenoterol hydrobromide, or any of the product’s excipients.

Populations Requiring Conditional Use

Use of this medicine requires a careful risk/benefit assessment by a healthcare professional in patients with certain comorbidities. These include insufficiently controlled diabetes mellitus, severe organic heart or vascular disorders (such as recent myocardial infarction), hyperthyroidism, and phaeochromocytoma. Caution is also specified for patients with severe airway obstruction.

Age and Physiological Status

While use is established for adults, administration to children should only occur with medical advice and appropriate supervision. For pregnancy, usual precautions are required, particularly during the first trimester. Fenoterol is excreted into breast milk, and safety in breast-fed infants has not been established, warranting caution for nursing women.

Interactions with other medicines and products

The interaction profile for Fenoterol hydrobromide (the active component of Berotec 0.05%) is primarily defined by pharmacodynamic effects as documented in official government regulatory information.

---

Documented Pharmacodynamic Interactions

Interaction Type	Interacting Agent(s)	Officially Documented Effect
Antagonism	beta-Adrenergic Blocking Agents	May result in a potentially serious reduction in bronchodilation.
Adverse Effect Enhancement	Other beta-Adrenergics and Sympathomimetic Agents	Increased risk of adverse cardiovascular reactions.
Adverse Effect Enhancement	Corticosteroids, Diuretics, Xanthine Derivatives (e.g., Theophylline)	May enhance the drug's hypokalemic effect, increasing the susceptibility to arrhythmias.
Adverse Effect Enhancement	Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs)	May enhance the beta-adrenergic action on the vascular system.

---

Regulatory Constraints and Scope

Regulatory documents mandate that co-administration with beta-adrenergic blocking agents must be avoided due to the significant risk of antagonism of the bronchodilatory action. The product’s official prescribing information requires particular caution for the hypokalemia-enhancing combinations, especially in patient populations with severe organic heart disorders or hyperthyroidism, where the interaction's consequence is more significant. Official labeling does not contain statements regarding interactions with food, alcohol, herbal products, or specific metabolic (CYP-mediated) or transporter-mediated mechanisms.

Selective beta2-Receptor Targeting and Activation

The mechanism of Fenoterol hydrobromide is initiated by the molecule acting as a partial agonist that selectively binds to and activates beta2-adrenoceptors, which are G-protein coupled receptors ( GPCRs) predominantly located on the smooth muscle cells of the bronchial tubes. This precise binding event transmits an activating signal that initiates the entire intracellular biochemical cascade, which regulates smooth muscle contractility.

---

Intracellular Relaxation and Smooth Muscle Modulation

The activation of the beta2-receptor triggers the cAMP second messenger system, which leads to the activation of Protein Kinase A ( PKA). This cascade results in the sequestration of intracellular calcium ( Ca^2+) and the functional inhibition of the contractile mechanism, resulting in a reduction of force generation in the bronchial smooth muscle cells.

---

Functional Constraint on Mediator Release

The drug engages secondary mechanisms by activating beta2-receptors present on other airway cells, such as mast cells. This activity results in a functional constraint on the release of endogenous substances like histamine and leukotrienes, which are compounds that otherwise signal or sustain airway smooth muscle contraction.

How Berotec 0.05% is Used: Administration Guidelines

Berotec 0.05% solution, containing fenoterol hydrobromide, is an inhalation medication used according to prescribed regimens. Its primary administration route is inhalation via a suitable nebulizing device; the solution is not intended for swallowing or injection.

---

Administration and Preparation Requirements

Usage of the 0.05% solution requires pre-administration processing. The measured dose must be diluted with a specific agent, generally physiological saline (0.9% sodium chloride), to a final volume of 3 mL to 4 mL. The diluted solution must be freshly prepared immediately prior to inhalation and any residual solution must be discarded after use. During administration, patients are advised to take care to prevent the solution or mist from entering the eyes.

---

Dosing Regimens

Dosing is individualized but adheres to specific ranges based on the clinical scenario. The medication is primarily intended for as-needed (symptom-driven) use, and increasing frequency of administration is considered a signal to consult a physician regarding the overall treatment plan.

Usage Scenario	Typical Adult Dose Range	Equivalent Fenoterol Content	Dilution/Frequency
Acute Relief	1.0 mL to 2.5 mL of 0.05% solution	0.5 mg to 1.25 mg	Dilute to 3 mL - 4 mL; As-needed
Prophylaxis (Pre-Exertion)	0.1 mL to 0.2 mL of 0.05% solution	0.05 mg to 0.1 mg	Dilute to 3 mL - 4 mL; 10–15 min prior

---

Population-Specific Use

Dosage adjustments are specifically outlined for pediatric patients. For children under 6 years, the solution is to be administered only under medical supervision, with a dose calculated at 0.1 mL/kg body weight (up to a 0.5 mL maximum), diluted to the required final volume. No explicit dose modifications are mandated for older adults or individuals with renal or hepatic impairment.

Research Evidence / Overview of Studies for Berotec 0.05%

Evidence for Use in Acute Symptomatic Airway Obstruction

The research base for Fenoterol hydrobromide, the active ingredient in Berotec 0.05%, includes numerous randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity in individuals with asthma and Chronic Obstructive Pulmonary Disease (COPD). Researchers designed these trials to explore short-term symptom changes, often comparing the medication to a placebo or other bronchodilator agents.

The studies monitored outcomes related to systemic or functional imbalance, specifically looking at changes in objective lung function metrics like the Forced Expiratory Volume in 1 second ( FEV1). Trials monitored measurements of pulmonary function over defined time intervals. Research described the time elapsed until the initial observed change in function and the duration of the observed change. Research gaps exist concerning long-term data for chronic, daily use of this monotherapy formulation.

Evidence for Prophylactic Use in Exercise-Induced Bronchoconstriction

Research has also explored the use of this medication in trials examining exercise-induced airway narrowing. These studies were structured as single-dose clinical trials and were applied in research contexts involving a standardized physical exercise challenge. Studies monitored physiological strain or stress, and the outcomes examined focused on the association between the medication's use and the measured change in FEV1 following the exercise challenge.

Data for this preventative scenario are still emerging. The evidence base is characterized by smaller sample sizes and comparison studies, meaning comparative evidence is lacking when viewed against large, contemporary placebo-controlled trials. The results apply only to the specific conditions under which these short-term studies were conducted, and data for long-term outcomes remain insufficient.

Areas of Research Uncertainty and Study Limitations

Many recent trials examined this agent as part of a fixed-dose combination, meaning research available for isolating the monotherapy’s contribution to reported patterns is limited. The quality of evidence varies across studies, particularly among older historical trials. Furthermore, evidence is limited for long-term outcomes; research data predominantly describes acute changes.

Key Studies & References

1. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma
2. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines (Regulatory/Guideline Context)

Common questions about Berotec 0.05% (FAQ)

---

Q: Is Berotec 0.05% a corticosteroid or an antibiotic?

According to the official product classification, Berotec 0.05% is a Selective Beta-2 Adrenergic Agonist (SABA). This means it is a bronchodilator that works to relax airway muscles. It is not classified as a corticosteroid (a type of anti-inflammatory drug) or an antibiotic.

---

Q: How long does the relief from Berotec 0.05% usually last?

Berotec 0.05% is classified as a short-acting medication, meaning its effect is temporary. Clinical data suggests the duration of action typically lasts for approximately four to six hours after inhalation.

---

Q: How quickly should I expect to feel the effect after using Berotec 0.05%?

Official product information indicates a very quick onset of action. The therapeutic effect is generally observed within five minutes of inhalation, with the peak effect usually reached within about 30 minutes of administration.

---

Q: Does Berotec 0.05% have any known interactions with caffeine?

Fenoterol is classified as a sympathomimetic agent. Combining the drug with other stimulants like caffeine may enhance the drug's beta-adrenergic action, which includes the risk of cardiovascular adverse reactions.

---

Q: What are the general risks if Berotec 0.05% is used more often than prescribed?

Official regulatory documents indicate that increasing the frequency of administration is considered a signal that a healthcare review of the overall treatment plan may be needed. Excessive use can potentially cause a stronger increase in heart rate and may lead to a decrease in serum potassium levels (hypokalaemia). It can also cause increased blood glucose levels.

---

Q: Are there any common over-the-counter medications that should not be taken with Berotec 0.05%?

Official labeling advises caution against co-administration with other sympathomimetic agents. Many non-prescription cold and flu remedies contain ingredients that fall into this class. Combining them with Berotec 0.05% increases the risk of specific cardiovascular side effects.

---

Q: Is Berotec 0.05% the same type of medication as Salbutamol (Albuterol)?

Both Berotec (Fenoterol) and Salbutamol (Albuterol) are classified as Short-Acting beta2-Adrenergic Agonists (SABAs) and function as effective bronchodilators. Some clinical studies have indicated that Fenoterol may be associated with a more pronounced increase in heart rate compared to Salbutamol.

---

Q: Are there known interactions between Berotec 0.05% and cold or flu remedies?

Official labeling advises caution regarding the co-administration of the drug with sympathomimetic agents. This general category includes certain active ingredients commonly found in cold and flu remedies, and the combination may increase the risk of side effects like tremors and palpitations.

---

Q: What does the '0.05%' concentration in the name Berotec 0.05% refer to?

The '0.05%' refers to the specific concentration of the active ingredient, fenoterol hydrobromide, in the aqueous solution. This formulation is prepared for inhalation delivery via a nebulizer.

---

Q: Is it documented that Berotec 0.05% affects blood sugar levels in any way?

Official warnings note that high doses of beta2-adrenergic agonists can potentially cause transient increases in plasma glucose, or hyperglycaemia. For this reason, official prescribing information notes that blood glucose monitoring may be necessary during treatment for individuals with diabetes.

---

Q: Are there any specific risks associated with using Berotec 0.05% past its expiration date?

Expiration dates define the period during which the product is guaranteed to maintain its strength, quality, and purity. Using the medication after this date is generally not advised because the active ingredient may have degraded, potentially making it less effective for treating acute symptoms.

---

Q: Why is Berotec 0.05% sometimes referred to by a different brand name in other regions?

The active molecule in the medication is Fenoterol hydrobromide. Like many pharmaceuticals, the same active ingredient may be marketed under various brand names (such as Berotec, Berodual, etc.) depending on the country or region where the product is sold.

---

Q: Is it normal to experience a dry throat or mouth after using Berotec 0.05%?

While not always classified among the most frequent adverse reactions, reports of dry mouth and throat irritation have been noted in post-marketing data for Fenoterol. These effects are typically categorized as less common reactions.

---

Q: Why is the drug administered as a solution for inhalation and not as a pill?

The inhalation route is the preferred administration method because it delivers the medication directly to the constricted airways. This allows for a rapid onset of action needed for acute symptoms while helping to limit the risk of systemic side effects compared to taking the drug orally.

How to Store and Dispose of Berotec 0.05%?

The official storage and disposal guidelines for Berotec 0.05% (fenoterol hydrobromide) inhalation solution are defined by regulatory requirements to maintain product stability and ensure public safety.

Official Storage Requirements

Condition	Regulatory Rule
Temperature	Store at temperatures consistent with label guidelines; avoid exposure to excessive heat (e.g., above 50 C for pressurized forms).
Protection	Keep the product in its original package and away from food and animal feedingstuffs.
Child Safety	Keep out of the sight and reach of children.

In-Use Stability and Discarding

Stability of Solution: The diluted solution must be freshly prepared and inhaled immediately. Any residual solution remaining after administration must be discarded. If a pressurized container has not been used for several days, it requires priming before administration.

Disposal Instructions

Unused or expired Berotec 0.05% must not be disposed of by flushing it down the sink or toilet. This measure prevents the medicine from entering surface water or the sanitary sewer system. The recommended methods are using community drug take-back programs or securely mixing the medicine with an undesirable substance (e.g., coffee grounds) before placing it in the household trash, after removing identifying information from the label.